肿瘤细胞治疗研究
英文原题：Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress.
嵌合抗原受体（CAR）-T 细胞治疗已成为发展最快的免疫治疗模式之一，在血液系统恶性肿瘤治疗中取得了显著成功，在实体瘤中也展现出令人鼓舞的结果。
嵌合抗原受体（CAR）T细胞疗法已成为发展最快的免疫治疗方式之一，在血液系统恶性肿瘤治疗中取得显著成功，在实体瘤中也呈现令人鼓舞的结果。然而，CAR-T疗法的应用受多种挑战限制，包括细胞扩增和持久性不理想、不良事件、理想靶点稀缺、强免疫抑制，以及复杂肿瘤微环境导致浸润不足。2024年欧洲肿瘤内科学会（ESMO）大会介绍了血液系统恶性肿瘤和实体瘤的新型CAR-T细胞疗法，重点展示克服上述挑战的策略，包括细胞因子调节、创新靶点、异基因产品开发、与mRNA疫苗协同、体内递送及条件性激活。
Chimeric antigen receptor (CAR)-T cell therapy has emerged as one of the most rapidly evolving modalities of immunotherapy, with substantial success in the treatment of hematological malignancies and encouraging outcomes in solid tumors. Yet, the efficacy of CAR-T therapy is hindered by challenges such as suboptimal expansion and persistence, adverse events, a scarcity of ideal targets, high immunosuppression, and insufficient infiltration due to the intricate tumor microenvironment, all of which limit its application. The 2024 European Society for Medical Oncology (ESMO) Congress presented novel CAR-T cell therapies for hematologic and solid malignancies, focusing on strategies such as cytokine modulation, innovative targets, allogeneic development, mRNA vaccine synergy, in vivo delivery and conditional activation to surmount these challenges.
MEMBER ACCOUNT
登录成功会直接打开下一页。
